Refine
Year of publication
Document Type
Way of publication
- Open Access (3)
Keywords
- CRISPR/Cas9 (2)
- multiplexing (2)
- ANCA (1)
- ANCA-associated vasculitis (1)
- Autoantikörper (1)
- Automatisierung (1)
- CytoBead technology (1)
- DNA damage response (DDR) (1)
- DNA damage signaling (1)
- HEp-2 (1)
- Immunfluoreszenz (1)
- LEDGF (1)
- LEDGF/p75 (1)
- antibodies against serine protease proteinase-3 (1)
- autoimmunity (1)
- automated IIF methods (1)
- automated interpretation of ANCA IIF (1)
- bioimage informatics (1)
- confirmatory testing (1)
- discrimination and classification of cytoplasmic ANCA (C-ANCA) and perinuclear ANCA (P-ANCA) (1)
- disease severity (1)
- double-strand break (DSB) (1)
- dsDNA (1)
- gH2AX (1)
- health-related quality of life (1)
- immunofluorescence microscopy (1)
- liver biochemistry (1)
- mDNA (1)
- microbead immunoassays (1)
- open source software (1)
- pattern recognition algorithms (1)
- platform for automated interpretation of cell-based IIF testing (1)
- primary sclerosing cholangitis (1)
- proteasome activator PA28gamma (1)
- screening (1)
- serology (1)
- survival (1)
- systemic autoimmune rheumatic disease (SARD) (1)
- ubiquitination (1)
- vasculitis (1)
Institute
Development of a Method for Multiplex Real-Time Analysis of Enzymati c Activity on a Microbead-Chip.
(2013)
Multiplex assessment of non-organ-specific autoantibodies with a novel microbead-based immunoassay
(2011)
Lens epithelium-derived growth factor splice variant of 75 kDa (LEDGF/p75) is an autoantigen over-expressed in solid tumors and acts as a stress-related transcriptional co-activator. Participation of autoimmune responses in the pathophysiology of benign prostatic hyperplasia (PBH) and a corresponding immunosuppressive therapy by TNFalpha antagonists has been recently suggested. Thus, autoAb testing could aid in the diagnosis of BPH patients profiting from such therapy. We generated CRISPR/Cas9 modified HEp-2 LEDGF knock-out (KO) and HEp-2 LEDGF/p75 over-expressing (OE) cells and examined IgG autoantibody reactivity to LEDGF/p75 in patients with prostate cancer (PCa, n = 89), bladder cancer (BCa, n = 116), benign prostatic hyperplasia (BPH, n = 103), and blood donors (BD, n = 60) by indirect immunofluorescence assay (IFA). Surprisingly, we could not detect elevated binding of autoAbs against LEDGF/p75 in cancer patients, but autoAb reactivity to LEDGF/p75 OE cells in about 50% of patients with BPH was unexpectedly significantly increased. Furthermore, a line immunoassay enabling the detection of 18 different autoAbs revealed a significantly increased occurrence of anti-dsDNA autoAbs in 34% of BPH patients in contrast to tumor patients and BD. This finding was confirmed by anti-mitochondrial (mDNA) autoAb detection with the Crithidia luciliae immunofluorescence test, which also showed a significantly higher prevalence (34%) of anti-mDNA autoAbs in BPH. In summary, our study provided further evidence for the occurrence of autoimmune responses in BPH. Furthermore, LEDGF/p75 over-expression renders HEp-2 cells more autoantigenic and an ideal target for autoAb analysis in BPH with a potential therapy consequence.
A highly sensitive detection of anti-neutrophil cytoplasmic antibodies to serine proteinase-3 (PR3-ANCAs) aids in the serological diagnosis of autoimmune liver disorders and the prediction of severity in primary sclerosing cholangitis (PSC). Here, we evaluate a novel third-generation ELISA for the detection of PR3-ANCAs. In total, 309 patients with PSC, 51 with primary biliary cholangitis (PBC), and 120 healthy blood donors (BD) were analyzed. For the survival analysis in PSC, the outcome was defined as liver-transplantation-free survival during the follow-up. Positive PR3-ANCA levels were found in 74/309 (24.0%) of patients with PSC. No BDs and one patient with PBC demonstrated PR3-ANCA positivity. PR3-ANCAs were revealed as independent predictors for a poor PSC outcome (study endpoint: liver transplantation/death, log-rank test, p = 0.02). PR3-ANCA positivity, lower albumin levels, and higher bilirubin concentrations were independent risks of a poor survival (Cox proportional-hazards regression analysis, p < 0.05). The Mayo risk score for PSC was associated with PR3-ANCA positivity (p = 0.01) and the disease severity assessed with a model of end-stage liver disease (MELD) and extended MELD-Na (p < 0.05). PR3-ANCAs detected by a third-generation ELISA are diagnostic and prognostic markers for PSC. Their wider use could help to identify patients who are at-risk of a more severe disease.